Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.56 |
| ▸ | FLT3 | P36888 | 3/20 | 0.56 |
| ▸ | CDK7 | P50613 | 2/20 | 0.56 |
| ▸ | CCNH | P51946 | 2/20 | 0.56 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034114 | 0.81 | KDR (0.70) | CDK1PTK2JAK2KDRALK | |
| SCHEMBL6033895 | 0.80 | CDK1 (0.64) | CDK1FLT3CDK7CCNHMNAT1 | |
| SCHEMBL21549440 | 0.79 | CDK7 (0.57) | CDK1FLT3CDK7CCNHMNAT1 | |
| SCHEMBL4518219 | 0.78 | RET (0.79) | CDK1FLT3CDK7CCNB1EGFR | |
| Diethylamine SCHEMBL7264463 | 0.77 | PTK2 (0.53) | CDK1EGFRPTK2JAK2SRC | |
| SCHEMBL14663329 | 0.77 | EGFR (0.60) | CDK1FLT3CDK7CCNHMNAT1 | |
| SCHEMBL29232127 | 0.77 | ALK (0.54) | CDK1FLT3CDK7CCNHMNAT1 | |
| SCHEMBL30956858 | 0.77 | ALK (0.54) | CDK1FLT3CDK7CCNHMNAT1 | |
| SCHEMBL11990226 | 0.75 | PLK1 (0.48) | CDK1FLT3CDK7CCNHMNAT1 | |
| SCHEMBL6033934 | 0.74 | PTK2 (0.52) | CDK1PTK2JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CDK1 58/4885FLT3 21/4885CDK7 455/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CDK1 59/4885FLT3 26/4885CDK7 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.